Pharma Q2fy23 Preview
The Pharma universe under our coverage could report aggregate Revenue/EBITDA/PAT growth of 5.6%/-4.8%/-2.2% YoY. Currency (Rs) has depreciated by 5.0%
263 Views
Pharma Q4FY22 Preview: Cost Pressure and Pricing Erosion Compress Margins
We expect companies under our Pharma coverage to report high singledigit growth (6.2% YoY), primarily driven by Injectable and Generic segment.
402 Views
Pharmaceutical Sector: Sequentially Flattish Quarter Expected
4QFY22 is expected to be a flattish quarter for most Pharma companies in our coverage universe. We expect a few companies to benefit from the US...
473 Views
Pakistan Market Outlook 2017
Pakistan market is expected to continue its uptrend in 2017 given tangible gains from China Pakistan Economic Corridor (CPEC) projects and rising...
572 Views
Pick of the Week - CIPLA LTD - 14 AUG 2023
Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics and portfolio deepening in the India, South...
306 Views